Puma Biotechnology Publishes P-II Trial (TBCRC041) Results of Alisertib for Endocrine-Resistant Advanced Breast Cancer in JAMA Oncology
Shots:
- The P-II trial (TBCRC041) evaluates alisertib as monotx. or in combination with fulvestrant. The trial was conducted through the Translational Breast Cancer Research Consortium
- Among 46 & 45 evaluable patients, efficacy results showed 9 patients experienced partial responses resulting in ORR of 19.6% & 20.0%, and m-DoR was 15.1mos. & 8.5mos. with 24wk. clinical benefit rate (41.3% & 28.9%), m-PFS was 5.6mos. & 5.4mos., respectively
- Baseline characteristics were well-balanced for 91 evaluable patients, patients in the combination arm had been prior treated with CT in the metastatic setting (47.8% in the alisertib monotx. & 68.9% in combination); 37% & 57.8% were prior treated with everolimus, 100% with CDK 4/6 inhibitors
Ref: Bussineswire | Image: Puma Biotechnology
Related Post:- Puma Biotechnology Presents P-II (SUMMIT) Basket Trial Results of Neratinib for EGFR Exon 18-Mutant NSCLC at EORTC/NCI/AACR 2022
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
